Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23383874 | 0.90 | TSHR (0.47) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23384162 | 0.90 | KMT2A (0.49) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23383873 | 0.89 | TSHR (0.55) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23182908 | 0.89 | KDM4E (0.54) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23383996 | 0.88 | MEN1 (0.50) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23383748 | 0.86 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23182881 | 0.85 | HDAC1 (0.61) | TDP1KMT2AMEN1HTTKDM4E | |
| SCHEMBL23383655 | 0.85 | SMN1; SMN2 (0.47) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23383656 | 0.85 | MEN1 (0.45) | CYP1A2CYP2C9CYP2C19TDP1KMT2A | |
| SCHEMBL23383779 | 0.84 | MEN1 (0.50) | CYP1A2CYP2C9CYP2C19TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145771-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145771-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | ATF4, EIF2B1, EIF4A1 | CYP1A2 2327/4885CYP2C9 3589/4885CYP2C19 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.